3,105 Shares in Cencora, Inc. $COR Purchased by Hartford Funds Management Co LLC

Hartford Funds Management Co LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) in the 4th quarter, HoldingsChannel.com reports. The firm bought 3,105 shares of the company’s stock, valued at approximately $1,049,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Oakworth Capital Inc. purchased a new position in Cencora during the fourth quarter worth about $26,000. Elyxium Wealth LLC purchased a new position in Cencora during the fourth quarter worth about $27,000. Archer Investment Corp grew its position in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares in the last quarter. IAG Wealth Partners LLC purchased a new position in Cencora during the third quarter worth about $30,000. Finally, Cloud Capital Management LLC purchased a new position in shares of Cencora in the 3rd quarter worth about $31,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Trading Up 1.7%

NYSE COR opened at $262.15 on Tuesday. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The stock has a 50-day moving average of $312.71 and a 200-day moving average of $338.72. The firm has a market cap of $51.00 billion, a PE ratio of 20.10, a price-to-earnings-growth ratio of 1.19 and a beta of 0.64.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period last year, the firm posted $4.42 EPS. The company’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts forecast that Cencora, Inc. will post 17.76 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s payout ratio is 18.40%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on COR shares. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Citigroup cut their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Barclays upped their price objective on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Finally, William Blair started coverage on Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.